Tempus announced it will distribute Predicta Biosciences’ whole-genome sequencing-based GenoPredicta assay for multiple myeloma, bringing the test into Tempus’ diagnostic ecosystem. GenoPredicta is designed to identify actionable DNA alterations and assess high-risk disease features using peripheral blood or bone marrow. The assay also supports treatment selection and minimal residual disease monitoring by consolidating multiple input types—flow cytometry, cytogenetics, and WGS—into one workflow. Tempus said the test can detect clonal evolution from as few as 50 tumor cells. The distribution deal aims to broaden access to genomic risk assessment while aligning both companies’ development needs for companion biomarker strategies in myeloma care.